Fuwai Hospital announced yesterday that China's self-developed heart valves are expected to be available in the next year. At that time, patients will use safe, effective and inexpensive "made in China" heart valves. String Pouch,String Canvas Pouch,String Pouch Bag,String Dust-Proof Pouch Dongguan C.Y. RedApple Industrial Limited , https://www.hpgbags.com
Each person's heart has four valves called the mitral, tricuspid, aortic, and pulmonary valves. These four thin valves are like the four doors of the heart - every time the heart contracts and relaxes, the valve switches once.
In the past, when the heart valve had a problem, the patient was subjected to thoracotomy to remove the damaged valve and implant a new artificial valve. In recent years, patients who are unable to perform conventional thoracotomy or have a high risk of surgery can be treated with interventional therapy to replace the valve through a catheter. Although the interventional valve replacement is a minimally invasive procedure, it has high technical requirements. This technology was applied to the clinic in China in 2010. At present, only a few large medical centers in the country can complete the operation. In addition, the development of artificial valves and other medical equipment is relatively lagging, which is one of the reasons why this technology cannot be applied on a large scale in China. It is understood that the current cost of importing a valve is about 250,000 yuan, plus surgery costs and other consumables, an operation costs about 300,000 yuan, which is expensive.
In order to enable more patients with high-risk valvular heart disease to be treated, China's research and development of artificial valves for minimally invasive treatment has been included in the “Twelfth Five-Year Planâ€. The project was organized and implemented by the famous cardiologist Gao Runlin. The National Cardiovascular Center Fuwai Hospital as the leader unit, combined with a number of well-known large hospitals to form a strong scientific research team, and finally developed a domestic heart valve. On September 7, 2011, he entered clinical trials, mainly for surgical inoperable and high-risk patients with severe aortic stenosis. 80 clinical trials have been successfully completed. It is reported that China's self-developed valves are expected to be listed in the next year. During the development of the project, the research team also found that the valvular disease in China has great differences with the foreign countries in terms of pathological characteristics and pathological morphology, which also indicates the necessity of self-developed domestic valves. This project has also created a technical route from valve evaluation to interventional operation. It is expected that the replacement valve will be widely promoted in many hospitals nationwide.
It is understood that after the operation of the domestic valve, the patient's treatment cost is expected to be reduced by about one-third to half.